Most drugs bind to a clearly defined macromolecular target that is complementary in terms of structure and chemistry. This observation is the basic paradigm of structure-based ligand design. Although this method first emerged in the 1980s, it has already become a powerful tool for pharmaceutical research. Much has been learned, however, since the first attempts to discover drugs on the basis of available biochemical and structural data. Nowadays, structure-based ligand design is an established method for creating drugs with new structural features, for modifying binding activities and pharmacokinetic properties, and for elucidating binding modes and structure-activity relationships. This volume presents the underlying principles of the approach and highlights real-life applications such as the discovery of HIV-protease inhibitors. It shows that structure-based ligand design has many advantages over other more traditional approaches to designing new drugs, providing it is employed properly and with a thorough knowledge of the pitfalls to avoid. The straightforward presentation and extensive list of references to the original literature as well as numerous color figures illustrating structural relationships make this volume an indispensable tool for every scientist working in the area of drug discovery.

Klaus Gubernator is the editor ofStructure-based Ligand Design, published by Wiley.

Hans-Joachim Bohm is the editor ofStructure-based Ligand Design, published by Wiley.

Raimund Mannhold is the series editor ofStructure-based Ligand Design, published by Wiley.

Hugo Kubinyi is the series editor ofStructure-based Ligand Design, published by Wiley.

Hendrik Timmerman is the series editor ofStructure-based Ligand Design, published by Wiley.

Rational Design of Bioactive Molecules Examples of Active Areas of Structure-Based Design From Renin to HIV-1 Protease Zinc Endoproteases: A Structural Superfamily Structure-Based Design of Potent Beta-Lactamase Inhibitors Inhibition of Sialidase Rational Design of Inhibitors of HIV-1 Reverse Transcriptase New Computational Approaches to Predict Protein-Ligand Interactions The Future of Structure-Based Design: A Worthy Precept?